Targeting metastatic cancer
By K. Ganesh, J. Massagué. Nature Medicine, 2021
854 citations recorded by the source corpus.
Despite recent therapeutic advances in cancer treatment, metastasis remains the principal cause of cancer death. Recent work has uncovered the unique biology of metastasis-initiating cells that results in tumor growth in distant organs, evasion of immune surveillance and co-option of metastatic microenvironments. Here we review recent progress that is enabling therapeutic advances in treating both micro- and macrometastases. Such insights were gained from cancer sequencing, mechanistic studies and clinical trials, including of immunotherapy. These studies reveal both the origins and nature of metastases and identify new opportunities for developing more effective strategies to target metastatic relapse and improve patient outcomes. Increased understanding of the biology of metastases allows improved targeting and outcomes for patients with both micro- and macrometastases.
Subfields: Biotechnology, Cancer Research, Oncology
View Paper: https://www.semanticscholar.org/paper/88e3b9f4cea1d4fba24cf1129c40c5550a46182f
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Biotechnology
In Cancer Research
In Oncology
Citations in the corpus
- Liquid Biopsy: From Discovery to Clinical Application. (2021, background): “Experimental models revealed that tumor cells are primed for dissemination before their release into the blood circulation by special niches in the primary tumor (147, 148).”
- New approaches and procedures for cancer treatment: Current perspectives (2021, background): “31 The stem cell cancer therapy approach confronted the following side effects: (1) tumorigenesis, (2) adverse events in allogeneic HSC transplantation, (3) drug toxicity and drug resistance, (4) increased immune responses and autoimmunity, and (5) viral infection.”